| Inhibition of COX1 in human platelets assessed as inhibition of A23187-stimulated TXB2 production at 100 uM pre-incubated for 30 mins before addition of A23187 measured after 10 mins by EIA - BioAssay Summary A new group of derivatives of salicylic acid containing NO-donor furoxans, and the related des-NO-furazans, were synthesized and evaluated as new aspirin-like molecules. Their stability was assessed in acid (pH 1) and physiological solutions (pH 7.4), and in human serum. No compound exhibited COX-inhibitory activity against COX-1 and COX-2 isoforms, when tested up to 100##M, respectively, on more .. |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||
Target Tested Compounds: Description: Title: Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans. Abstract: A new group of derivatives of salicylic acid containing NO-donor furoxans, and the related des-NO-furazans, were synthesized and evaluated as new aspirin-like molecules. Their stability was assessed in acid (pH 1) and physiological solutions (pH 7.4), and in human serum. No compound exhibited COX-inhibitory activity against COX-1 and COX-2 isoforms, when tested up to 100##M, respectively, on isolated platelets and on monocytes. Phenylsulfonyl- and cyano-substituted furoxans inhibited platelet aggregation induced by collagen in human platelet-rich plasma, through a cGMP dependent mechanism. Furoxan derivatives displayed cGMP-dependent vasodilator activities, tested on rat aorta strips precontracted with phenylephrine. All products showed anti-inflammatory activity similar to that of ASA, tested on rats by the carrageenan-induced paw edema assay. Unlike ASA, all products showed markedly reduced gastrotoxicity in a rat lesion model. (PMID: 21906954) Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 96 ChEMBL target type: Target is a single protein chain Result Definitions
Data Table (Concise)
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||